SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving
Possible Securities Fraud Violations by Certain Officers and Directors of INSYS Therapeutics, Inc.
Levi & Korsinsky announces it has commenced an investigation of INSYS Therapeutics, Inc. (NASDAQ: INSY) concerning possible
violations of federal securities laws.
On March 15, 2017, INSYS announced that it would delay the release of its financial results for the quarter and year ended
December 31, 2016. INSYS advised investors that "[t]he Audit Committee of the Company’s Board of Directors has been conducting an
independent review of the Company's processes related to estimation of, and increases to, certain sales allowances recorded during
2016, with a potential reduction of 2015 net revenue and pre-tax income not expected to exceed $5 million, as well as extended
payment terms offered to certain customers during the third quarter of 2016." Following this news, shares of INSYS were down more
than 5% on intraday trading on March 16, 2017. To obtain additional information, go to:
http://zlk.9nl.com/insys-insy
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, Connecticut and Washington D.C. The firm’s attorneys have
extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170316006123/en/